Discontinuing combination antiretroviral therapy during the first trimester of pregnancy: insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count.

A. M. Bucceri, E. Somigliana, R. Matrone, C. Uberti-Foppa, P. Viganò, M. Vignali

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Options for human immunodeficiency virus-1-infected women who are already receiving antiretroviral medications when they become pregnant include the continuation or discontinuation of the therapy during the first trimester. These two strategies are compared in terms of plasma human immunodeficiency virus viral load and CD4 cell count. STUDY DESIGN: Seventy women who attended the II Department of Obstetrics and Gynecology were identified. Four different periods for laboratory evaluations were decided: presuspension, suspension, second trimester, and third trimester. RESULTS: Thirty-two women (46%) discontinued antiretroviral therapy; 38 women (54%) did not. Whereas plasma HIV virus viral load and CD4 cell count did not significantly vary during pregnancy in patients who did not interrupt the therapy, these two variables were influenced significantly by the discontinuation of treatment (P

Original languageEnglish
Pages (from-to)545-551
Number of pages7
JournalAmerican Journal of Obstetrics and Gynecology
Volume189
Issue number2
Publication statusPublished - Aug 2003

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Discontinuing combination antiretroviral therapy during the first trimester of pregnancy: insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count.'. Together they form a unique fingerprint.

  • Cite this